A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma.
aneurysm rupture
arterial aneurysm
metastatic renal cell carcinoma
pazopanib
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
24
08
2021
accepted:
21
09
2021
pubmed:
30
10
2021
medline:
9
8
2022
entrez:
29
10
2021
Statut:
ppublish
Résumé
Pazopanib is a vascular endothelial growth factor inhibitor that is used in the treatment of metastatic renal cell carcinoma. Post market reports demonstrate an increasing awareness of the association of arterial aneurysms and dissections with vascular endothelial growth factor inhibitor use, although, few reports exist for pazopanib. Here we report a 69-year-old patient with minimal cardiovascular risk factors who developed a rupture of a splenic arterial aneurysm after more than 5 years of effective treatment with pazopanib for metastatic renal cell carcinoma. This case report outlines the necessity to monitor patients while on pazopanib, even when there are minimal risk factors and long periods of tolerance.
Sections du résumé
BACKGROUND
Pazopanib is a vascular endothelial growth factor inhibitor that is used in the treatment of metastatic renal cell carcinoma. Post market reports demonstrate an increasing awareness of the association of arterial aneurysms and dissections with vascular endothelial growth factor inhibitor use, although, few reports exist for pazopanib.
CASE
Here we report a 69-year-old patient with minimal cardiovascular risk factors who developed a rupture of a splenic arterial aneurysm after more than 5 years of effective treatment with pazopanib for metastatic renal cell carcinoma.
CONCLUSION
This case report outlines the necessity to monitor patients while on pazopanib, even when there are minimal risk factors and long periods of tolerance.
Identifiants
pubmed: 34713631
doi: 10.1002/cnr2.1567
pmc: PMC9351660
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1567Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):387-398
pubmed: 29706106
Circulation. 2017 Feb 21;135(8):815-817
pubmed: 28223329
Crit Rev Oncol Hematol. 2017 Dec;120:151-162
pubmed: 29198329
Am J Hypertens. 2016 Feb;29(2):158-62
pubmed: 26031304
Cancer Rep (Hoboken). 2022 Aug;5(8):e1567
pubmed: 34713631
Aktuelle Urol. 2014 Mar;45(2):132-4
pubmed: 24700069
Vasc Med. 2021 Oct;26(5):526-534
pubmed: 33840328